Icon Genetics

Halle, Germany Founded: 1999 • Age: 27 yrs Acquired By Denka
Biopharmaceuticals and proteins are developed using green plants as hosts.
Annual revenue - Latest available
Total funding $14.6M 2 rounds
Employees 25 Tracked headcount
Investors 3 Known backers
Products 2 Services tracked
Competitors 10 Brand Intelligence

About Icon Genetics

Icon Genetics is a company based in Halle (Germany) founded in 1999 was acquired by Denka in August 2015. Icon Genetics has raised $14.6 million across 2 funding rounds from investors including Denka, IBG Beteiligungsgesellschaft Sachsen-Anhalt and CFH. The company has 25 employees as of December 31, 2021. Icon Genetics offers products and services including magnICON® Platform and Recombinant Proteins. Icon Genetics operates in a competitive market with competitors including Core Biogenesis, Qkine, Future Fields, Protera and Algenex, among others.

  • Headquarter Halle, Germany
  • Employees 25 as on 31 Dec, 2021
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Icon Genetics Gmbh
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $14.6 M (USD)

    in 2 rounds

  • Latest Funding Round
    $2.6 M (USD), Series A

    Mar 04, 2002

  • Investors
    Denka

    & 2 more

  • Employee Count
    25

    as on Dec 31, 2021

  • Acquired by
    Denka

    (Aug 06, 2015)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Icon Genetics

Icon Genetics offers a comprehensive portfolio of products and services, including magnICON® Platform and Recombinant Proteins.

Product name locked
Category locked
Primary

Technology for transient expression of recombinant proteins in plants.

Product name locked
Category locked
Locked

Proteins for vaccines and diagnostics via plant-based production.

Funding Insights of Icon Genetics

Icon Genetics has successfully raised a total of $14.6M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $2.6 million completed in March 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Icon Genetics

Icon Genetics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Denka, IBG Beteiligungsgesellschaft Sachsen-Anhalt and CFH.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
-
Locked Locked Locked
Equity partnerships are provided for startups and mid-sized companies in Saxony.
Locked Locked Locked
Manufacturer of calcium carbide and chemical fertilizers
Locked Locked Locked
Premium access

Investor details for Icon Genetics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Icon Genetics

Investments
Premium access

Investment portfolio details for Icon Genetics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Icon Genetics

Premium access

Detailed financials for Icon Genetics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Icon Genetics Comparisons

Icon Genetics Primary company
Description
Biopharmaceuticals and proteins are developed using green pl...
Location
Halle, Germany
Founded Year
1999
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
25
As of 2021
Premium access

Peer comparison for Icon Genetics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Icon Genetics

Icon Genetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Core Biogenesis, Qkine, Future Fields, Protera and Algenex, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
UBaaS platform for plant-based recombinant protein bioproduction is offered.
Locked Locked Locked
Animal-free growth factors are developed for life science applications.
Locked Locked Locked
Serum-free bioactive growth factors and recombinant proteins are biomanufactured.
Locked Locked Locked
Protein-based enzyme technologies are developed using deep learning algorithms.
Locked Locked Locked
Developer of recombinant biologics for animal and human health
Premium access

Detailed competitors of Icon Genetics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Icon Genetics

Premium access

Complete news archive for Icon Genetics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Icon Genetics

Icon Genetics was founded in 1999 and raised its 1st funding round 1 year after it was founded.

Icon Genetics is headquartered in Halle, Germany. It is registered at Halle, Sachsen-anhalt, Germany.

Icon Genetics is a funded company, having raised a total of $14.6M across 2 funding rounds to date.

As of Dec 31, 2021, the latest employee count at Icon Genetics is 25.

Icon Genetics discovers and develops new biopharmaceuticals and high-value protein products using green plants as production hosts. They have developed new generation production platforms and product prototypes for pharmaceutical, animal health and chemical biotech markets. They offer new plant engineering technologies which address speed, yield, precision, expression control and safety of transgene management in plants. Its products include Transgene Operating Systems, a suite of technologies, including nuclear transformation of plants based on translational (promoterless), translation-fusion, and polycistronic vectors, as well as vectors that utilize vector assembly in planta or RNAprotein trans-splicing; plastid transformation that allows construction of transplastomic hosts for high-yield production of specialty proteins in chloroplasts; and pro-viral transfection of plants that provides advantages of fast amplification processes in a plant. The company also offers magnICON system for rapid genevector assembly and optimization, as well as for high yieldhigh throughput expression of genes in planta; lexICON system allows DNA bar-coding of genetically modified plants; and rubICON, a hybrid seed production and trait control system. In January 2006, the Company has been acquired by Bayer Innovation GmbH, a wholly owned subsidiary of Bayer AG. In January 2007,Icon Genetics AG has been merged into Icon Genetics GmbH. In January 2012, ICON has been acquired by Nomad Bioscience GmbH, Munich, Germany. In Aug 2015, the company was acquired by Japans Denka.

Icon Genetics's top competitors include Future Fields, Qkine and Oxford Expression Technologies.

Icon Genetics offers magnICON® Platform and Recombinant Proteins.

Icon Genetics has 3 investors. Key investors include Denka, IBG Beteiligungsgesellschaft Sachsen-Anhalt, and CFH.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available